Until the Spring Festival of 2024, the popularity of "Erbin" cultural tourism is still undiminished. Since the winter, the topic of Northeast tourism has been dominating the major social networks, and then there is a slogan that has resounded for 20 years - "Northeast Revitalization".
From Harbin Pharmaceutical No. 6 Factory to Tonghua Dongbao leading China's biopharmaceuticals to go overseas; From the 13-year struggle of Hengli Petrochemical to the second transformation of Jidian Co., Ltd., it has built a ...... of the "hydrogen-based green energy" industrial chain
What surprises people is not only the Northeast tourism, but also the entire Northeast fertile soil.
Tourists play in the Harbin Ice and Snow World Park. **Xinhua.
The "Northeast Louvre" is lit up
Together with Harbin Cultural Tourism, there is also an old pharmaceutical factory with a history of several decades - Harbin Pharmaceutical No. 6 Factory, which is also called the "Northeast Louvre" by netizens because of its exotic architectural body. During the Spring Festival, the reporter of "International Financial News" went to this new "check-in place" with an average of more than 10,000 tourists per day.
Coming to the door of Harbin Pharmaceutical No. 6 Factory, the reporter noticed that the temperature of minus ten degrees that day did not stop the enthusiastic footsteps of tourists, and there were still many tourists who came to line up to enter the factory. In fact, Harbin Pharmaceutical No. 6 Factory is not in the center of the city, and it is also a certain distance from well-known attractions such as ** Street and Flood Control Memorial Tower, but there are still tourists who are willing to come to see the scenery. On the way to Harbin Pharmaceutical No. 6 Factory, the driver told reporters: "The recent destinations for picking up customers are nothing more than these three: Ice and Snow World, Harbin Pharmaceutical No. 6 Factory, and ** Street." ”
In fact, Harbin Pharmaceutical No. 6 Factory is not always open for tourists. Under the soaring popularity of cultural tourism in Harbin, many tourists expressed on social platforms that they wanted to see the "lights" of Harbin Pharmaceutical No. 6 Factory. Subsequently, Harbin Pharmaceutical Group decided to open the door free of charge from January 16. Some locals told the "International Financial News" reporter that it is unexpected that the No. 6 Harbin Pharmaceutical Factory can become a check-in point this year, after all, the building of the No. 6 Harbin Pharmaceutical Factory has existed for many years, and I didn't expect it to be discovered by so many people now. Prior to this, Harbin Pharmaceutical No. 6 Factory had also entered the public's field of vision due to online rumors that it would be converted into a bathing center.
Harbin Pharmaceutical No. 6 Factory was founded in the 70s of the last century, and its parent company, Harbin Pharmaceutical Group Co., Ltd., was established in 1993, and was listed on the Shanghai ** Stock Exchange in that year, becoming the first listed company in China's pharmaceutical industry and the first listed company in Heilongjiang Province. In the year of listing, Harbin Pharmaceutical Group achieved an operating income of 234.6 billion yuan, pay 50 million yuan in employee salaries, and pay taxes 16.6 billion yuan, achieving a net profit of 13.7 billion yuan. In the 90s of the last century, the revenue of more than 2 billion yuan was second to none among all A-share listed companies that year. From 2006 to 2010, Harbin Pharmaceutical Group always maintained the first position in the list of China's top 100 pharmaceutical industries by the Ministry of Industry and Information Technology.
As a pharmaceutical company with a history of more than 70 years, it has many brand assets, covering different fields such as health, respiratory, gastrointestinal, and chronic diseases. In order to give full play to this advantage, Harbin Pharmaceutical began to revive various brands through digital marketing, academic promotion, and a combination of online and offline methods, and established a new brand of "Harbin Pharmaceutical Health" in 2022.
Although it remains to be seen whether health care products can bring sustainable growth to Harbin Pharmaceutical, as a veteran pharmaceutical company in Northeast China, Harbin Pharmaceutical's "light on" again is undoubtedly a microcosm of the revitalization of Northeast China. The latest third quarter report of 2023 shows that Harbin Pharmaceutical's revenue in the first three quarters was 1149.4 billion yuan, a year-on-year increase of 1505%；Net profit attributable to the parent company 2900 million yuan, a year-on-year increase of 8572%。
Twenty years of revitalization "march".
2023 is not only a year of explosion in Harbin, but also the 20th anniversary of the implementation of the Northeast Revitalization Strategy. As the "granary of rice bags" for the Chinese people, the "cradle" of the Republic's industry, and an important link connecting the Northeast Asian economic circle, the "march" of reform and revitalization of this black fertile land is playing a new movement.
In September 2023, the symposium on promoting the comprehensive revitalization of Northeast China in the new era was held in Harbin, emphasizing the need to adhere to the combination of increasing support and stimulating endogenous power, made a comprehensive deployment for promoting the revitalization of Northeast China in the new era, and put forward a number of specific measures, including promoting industrial innovation with scientific and technological innovation, actively cultivating strategic emerging industries, continuing to deepen the reform of state-owned enterprises, implementing special actions for the revitalization of state-owned enterprises, improving the level of opening up and cooperation with domestic and foreign countries, and supporting the comprehensive revitalization of Northeast China with high-quality population development.
In October 2003, the Communist Party of China officially issued the "Several Opinions on the Implementation of the Revitalization Strategy of Old Industrial Bases in Northeast China", which became the beginning of the revitalization of old industrial bases in Northeast China. On November 24, 2023, the State-owned Assets Supervision and Administration Commission (SASAC) held a special meeting of enterprise leaders, emphasizing that it is necessary to take the initiative to support and promote new breakthroughs in the comprehensive revitalization of Northeast China.
Over the past 20 years, the state has issued 4 general programmatic documents, launched hundreds of preferential support policies, and leaders have visited Northeast China intensively to cheer for the development of Northeast China. From the perspective of financial investment alone, from 2003 to 2022, the total transfer payments to Liaoning, Jilin and Heilongjiang reached 3,255.3 billion yuan, 2,862.8 billion yuan and 5,884.7 billion yuan respectively, with a cumulative transfer payment scale of nearly 11 trillion yuan.
Now, a new round of the Northeast revitalization strategy has opened a new chapter in the development of Northeast China. Li Hongbiao, a special think tank expert of the China Northeast Revitalization Research Institute, previously said that compared with the previous Northeast revitalization, the new round of Northeast revitalization has clearer goals, a broader path, and a clearer orientation. The introduction of the top-level design will inject stronger impetus into the development of Northeast China, and it is expected that in the future, Northeast China will achieve new breakthroughs in all-round opening up, industrial upgrading, attracting talents, and regional economic integration, especially the huge economic energy contained in the Far East market will be further excavated and released.
Northeast enterprises continue to make efforts
Northeast China is the old industrial base of China, and in the early days, the Northeast industrial base with Dalian, Shenyang, Harbin and Changchun as the axis was formed. There are industrial cities such as Qiqihar, Daqing, Jilin, Anshan, Benxi and so on. Liaoning is mainly based on steel and machinery heavy industries, Jilin is mainly based on automobiles and emerging biomedicine, and Heilongjiang focuses on oil and coal industries. During the Spring Festival, the reporter of "International Financial News" also noticed that after the explosion of cultural tourism in Harbin, the Northeast revitalization concept stock enterprises have held back their internal strength and intend to make a difference in 2024.
Insulin faucet Tonghua Dongbao:
It is necessary to fight the tough battle of "China's biopharmaceuticals going overseas".
Under the favorable policy, the Northeast enterprises bred from this black soil are also silently making efforts. Su Fan, secretary of the board of directors of Tonghua Dongbao, said in an interview with the reporter of "International Financial News", "After the fire of Harbin cultural tourism, the concept of revitalization of Northeast China has risen again. As a member of the Northeast enterprise, for more than 20 years, Tonghua Dongbao has been based on the Northeast market from the beginning, and then to the national market, and by 2024, a tough battle we are ready to fight is to knock on the door of the European and American pharmaceutical markets. For this reason, we have actually been laying out for many years. Although it is a private enterprise, Tonghua Dongbao hopes to be able to base itself on the domestic market while more firmly implementing the internationalization strategy, fighting the tough battle of 'Chinese biopharmaceuticals going overseas', and making due contributions to China's biopharmaceuticals to the world. ”
How to implement the internationalization strategy? Su Fan said that the company began to continue to promote the registration and certification of insulin glargine and insulin aspart in the EU and developing countries at the beginning of 2020. In 2023, Tonghua Dongbao has made many key stages of progress in the overseas expansion of its products, for example, in February 2023, the marketing authorization application for human insulin injection was accepted by the European Medicines Agency; In September 2023, it signed a strategic cooperation agreement with Jianyou Co., Ltd. on the entry of three insulin injections, glargine, aspart, and lispro into the U.S. market; In December 2023, after Tonghua Dongbao liraglutide injection was approved for marketing in China, it started the work of linking the network to various provinces and cities in China, and at the same time accelerated the registration and application process of liraglutide in 17 overseas emerging markets in cooperation with Sinovac Pharmaceutical. Up to now, the registration application documents for liraglutide in 8 overseas countries have been submitted.
With the continuous improvement of the overall strength of China's pharmaceutical enterprises and the continuous enhancement of international competitiveness, domestic pharmaceutical companies have entered the international market. In recent years, Tonghua Dongbao has also continued to accelerate the process of internationalization. "Why are we going to fight a tough battle in 2024? Because industry insiders know that among all overseas markets, the U.S. pharmaceutical market has the highest quality standards, and the market size has remained the world's largest for a long time. As a leading domestic insulin enterprise and a leading domestic manufacturer in the industry, Tonghua Dongbao has been deeply engaged in the field of endocrinology and metabolism for many years, and is a high-quality biological drug that can compete with similar overseas products, and it is time to explore the market overseas. ”
Tonghua Dongbao's human insulin API has passed the EU GMP certification as early as 2013, and has been exported to Poland, Georgia, Bangladesh and other European and neighboring Asian countries, and has established different degrees of business contacts with enterprises in Eastern Europe, Southeast Asia, West Asia, Central Asia, the Middle East, Africa, South America and Central America. Su Fan said that the advantages and core competitiveness of Tonghua Dongbao's internationalization lie in its production technology precipitation, excellent product quality (developed countries such as Europe and the United States have stricter requirements), large-scale production capacity, etc. With the continuous realization of the company's pipeline and the increasing enrichment of the product system, in addition to human insulin, the company is introducing more high-quality products, such as insulin analogues, GLP-1RA and a class of innovative drugs to the international market, and gradually promoting the company's internationalization strategy.
Private petrochemical giant Hengli Petrochemical:
High-quality development is the last word
The "dual carbon" goal in the new era has been established, and energy and chemical enterprises in Northeast China have also regarded green manufacturing and carbon reduction goals as their own responsibilities and practiced their own social responsibilities.
In 2024, Hengli Group ushered in the 30th anniversary celebration of its establishment. Facing the future, Chen Jianhua, chairman of Hengli Group, once again made bold statements: Hengli Group will accelerate the construction of a world-class enterprise, create a new benchmark for the global industry, and promote subversive changes in the industry. Chen Jianhua said that the 30 years of development of Hengli fully prove that as long as the confidence is not lying flat, facing difficulties and not giving up, and the word "dry" is not relaxed, the current difficulties are all difficulties in development, problems in progress and growing troubles. Standing at a new starting point, Chen Jianhua hopes that all Hengli people will sum up experience, reflect deeply, and continue to draw on the strength of high-quality development.
In 2010, in response to the call of the Northeast Revitalization Strategy, Hengli Group entered Changxing Island, Dalian, which opened the prelude to the construction of Changxing Island Petrochemical Industrial Park. In the following 13 years, the Hengli Changxing Island Industrial Park project created a whole industrial chain layout from "a drop of oil to a piece of cloth", and continuously accelerated the pace of extending the chain and supplementing the chain, and successively built a number of chemical industrial parks including Hengli Polyester Technology Industrial Park. According to the 2023 performance forecast, Hengli Petrochemical's net profit last year reached 6.9 billion yuan, an increase of 197 percent year-on-year63%。
In the new year, Chen Jianhua raised high-quality development to the strategic level, and he emphasized that high quality is the last word for the steady development of Hengli Group in the future. The group has been preparing social responsibility reports since 2021 and attaches great importance to environmental issues, and in 2022, Hengli Petrochemical has invested 24.8 billion yuan, and its national "green factory" increased to five, namely Hengli Petrochemical (Dalian), Hengli Refining & Chemical, Hengli Chemical Fiber, Hengke New Materials, Hengli Chemical, Deli Chemical Fiber, the above actual investment directly reflects the importance and practice of a private enterprise to green development.
Power leader Jidian shares:
Accelerate the formation of new quality productive forces for the revitalization of Northeast China
It's time to straighten your spine. In Jilin, from the 10 million kilowatt base of "integration of wind, solar, fire and storage" in the Baicheng area of Hanhai, to the new energy and pumped storage project in Wangqing County, the old revolutionary area, and then to the "zero carbon factory" of the Audi FAW New Energy Automobile Industrial Park in central Jilin, and the hydrogen energy application base of hydrogen-based green energy and hydrogen-doped gas turbines, Jidian Electric Co., Ltd. is promoting the implementation of all-factor energy industries such as "wind, light, fire, hydrogen, storage, and biomass" in the province, helping the comprehensive revitalization of Jilin in the new era and taking the lead in achieving new breakthroughs.
In 2018, Jidian Co., Ltd., which successfully transformed into a new energy enterprise, made the "second transformation", based on the high-quality wind and solar resources in Jilin Province, and explored the development path of the hydrogen energy industry with green power transformation. In 2023, Kyrgyzstan Electric Co., Ltd., which has grown into a power leader, will hand over a "hydrogen-based green energy" industrial chain to the Northeast Revitalization Strategy with a number of "hydrogen-based green energy" industrial chain achievements such as the world's largest green ammonia project - Da'an Wind and Solar Energy to Green Hydrogen Synthesis and Ammonia Integration Demonstration Project, the other end of the "Changbai Hydrogen Energy Corridor", and the "Horse Racing Project" of the National Development and Reform Commission - China-South Korea Demonstration Zone "Renewable Energy + PEM Hydrogen Production + Hydrogen Refueling".
At the 2024 work conference of Jidian Co., Ltd., Cai Yanfu, Secretary of the Party Committee and Chairman of Jidian Co., Ltd., issued a strong signal, "At present, on the basis of our development has achieved a certain scale, we must strive for the new strategic transformation period and make the four main lines of development bigger and stronger." "The latest performance forecast shows that Kyrgyzstan Electric Co., Ltd. is expected to achieve a net profit of 8900 million-9400 million yuan, a year-on-year increase of 3193%-39.34%。
While the popularity of Harbin cultural tourism has attracted consumption flow to the Northeast, it has also injected new ideas and new vitality into the revitalization of the Northeast. Investors in the secondary market are also looking forward to these old Northeast companies to seize the opportunity and shine new light.